Updated Phase 1 Results for ALN-APP Presented at 2023 Alzheimer’s Association International Conference

17 Jul, 2023 Updated Phase 1 Results for ALN-APP Presented at 2023 Alzheimer’s Association International Conference

We presented updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA), at the 2023 Alzheimer’s Association International Conference (AAIC).

Cohen et al. “Interim Phase 1 Part A Results for ALN-APP, the First Investigational RNAi Therapeutic in Development for Alzheimer’s Disease”